These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12094551)

  • 21. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
    Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK
    J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterization and inhibition of the type II DNA topoisomerase coded by African swine fever virus.
    Coelho J; Ferreira F; Martins C; Leitão A
    Virology; 2016 Jun; 493():209-16. PubMed ID: 27060564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA
    Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
    O'Reilly EK; Kreuzer KN
    Biochemistry; 2002 Jun; 41(25):7989-97. PubMed ID: 12069589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.
    Kreuzer KN
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):339-47. PubMed ID: 9748648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA topoisomerase inhibitors.
    Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
    Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607
    [No Abstract]   [Full Text] [Related]  

  • 30. Topoisomerase II inhibitors.
    Hande KR
    Cancer Chemother Biol Response Modif; 2003; 21():103-25. PubMed ID: 15338742
    [No Abstract]   [Full Text] [Related]  

  • 31. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes.
    Davies SL; Popert R; Coptcoat M; Hickson ID; Masters JR
    Int J Cancer; 1996 Jan; 65(1):63-6. PubMed ID: 8543398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
    Keller BA; Patel S; Fisher LM
    Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):329-39. PubMed ID: 9164874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
    Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
    Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
    Thapa U; Thapa P; Karki R; Yun M; Choi JH; Jahng Y; Lee E; Jeon KH; Na Y; Ha EM; Cho WJ; Kwon Y; Lee ES
    Eur J Med Chem; 2011 Aug; 46(8):3201-9. PubMed ID: 21601964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topoisomerase II inhibitors.
    Martincic D; Hande KR
    Cancer Chemother Biol Response Modif; 2005; 22():101-21. PubMed ID: 16110609
    [No Abstract]   [Full Text] [Related]  

  • 38. DNA topoisomerases: from a laboratory curiosity to a subject in cancer chemotherapy.
    Wang JC
    NCI Monogr; 1987; (4):3-6. PubMed ID: 2819727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
    Gatto B; Capranico G; Palumbo M
    Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line.
    Binaschi M; Giaccone G; Gazdar AF; De Isabella P; Ricotti GC; Capranico G; Zunino F
    J Natl Cancer Inst; 1992 Nov; 84(22):1710-6. PubMed ID: 1331483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.